FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111479968> ?p ?o ?g. }

• W2111479968 endingPage "4411" @default.
• W2111479968 startingPage "4405" @default.
• W2111479968 abstract "Purpose Numerous prospective and retrospective studies have concluded that elderly patients (≥ 70 years old) achieve a similar survival benefit, with acceptable toxicity, from first-line cytotoxic chemotherapy for the treatment of advanced non–small-cell lung cancer (NSCLC) compared with their younger counterparts. However, few published data exist on the efficacy and tolerability of second-line cytotoxic therapy in this population. Patients and Methods Retrospective analysis of a large second-line trial was performed. Data from 571 patients randomly assigned to docetaxel 75 mg/m 2 or pemetrexed 500 mg/m 2 every 3 weeks were analyzed for efficacy and toxicity comparisons between age groups and treatment arms. Results Eighty-six of 571 patients (15%) were ≥ 70 years old, similar to rates of elderly observed in the first-line setting. Elderly patients receiving pemetrexed (n = 47) or docetaxel (n = 39) had a median survival of 9.5 and 7.7 months compared with 7.8 and 8.0 months for younger patients receiving pemetrexed (n = 236) or docetaxel (n = 249), respectively. Elderly patients treated with pemetrexed had a longer time to progression and a longer survival than their counterpart patients treated with docetaxel (not statistically significant). Febrile neutropenia was less frequent in elderly patients treated with pemetrexed (2.5%) compared with docetaxel (19%; P = .025), with only one death as a result of toxicity (docetaxel arm). Conclusion Elderly patient participation was similar to rates observed in the first-line setting. There was no significant difference in outcome or toxicity between elderly and younger patients. For elderly patients with advanced NSCLC and good performance status, second-line cytotoxic therapy is appropriate. In this subset, pemetrexed produced a more favorable toxicity profile." @default.
• W2111479968 created "2016-06-24" @default.
• W2111479968 creator A5039878116 @default.
• W2111479968 creator A5044887899 @default.
• W2111479968 creator A5048660181 @default.
• W2111479968 creator A5071670695 @default.
• W2111479968 creator A5073338061 @default.
• W2111479968 creator A5074428655 @default.
• W2111479968 creator A5074789425 @default.
• W2111479968 creator A5075347427 @default.
• W2111479968 creator A5080669646 @default.
• W2111479968 creator A5089930850 @default.
• W2111479968 creator A5090256464 @default.
• W2111479968 date "2006-09-20" @default.
• W2111479968 modified "2023-10-17" @default.
• W2111479968 title "Elderly Patients Benefit From Second-Line Cytotoxic Chemotherapy: A Subset Analysis of a Randomized Phase III Trial of Pemetrexed Compared With Docetaxel in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer" @default.
• W2111479968 cites W1839238860 @default.
• W2111479968 cites W1991818094 @default.
• W2111479968 cites W2016156617 @default.
• W2111479968 cites W2029962381 @default.
• W2111479968 cites W2066059360 @default.
• W2111479968 cites W2130652363 @default.
• W2111479968 cites W2134667653 @default.
• W2111479968 cites W2137009016 @default.
• W2111479968 cites W2138297714 @default.
• W2111479968 cites W2140872365 @default.
• W2111479968 cites W2141765139 @default.
• W2111479968 cites W2145653040 @default.
• W2111479968 cites W2156127723 @default.
• W2111479968 cites W2160131381 @default.
• W2111479968 cites W2165048128 @default.
• W2111479968 cites W2167014559 @default.
• W2111479968 doi "https://doi.org/10.1200/jco.2006.06.7835" @default.
• W2111479968 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16983108" @default.
• W2111479968 hasPublicationYear "2006" @default.
• W2111479968 type Work @default.
• W2111479968 sameAs 2111479968 @default.
• W2111479968 citedByCount "136" @default.
• W2111479968 countsByYear W21114799682012 @default.
• W2111479968 countsByYear W21114799682013 @default.
• W2111479968 countsByYear W21114799682014 @default.
• W2111479968 countsByYear W21114799682015 @default.
• W2111479968 countsByYear W21114799682016 @default.
• W2111479968 countsByYear W21114799682017 @default.
• W2111479968 countsByYear W21114799682018 @default.
• W2111479968 countsByYear W21114799682019 @default.
• W2111479968 countsByYear W21114799682020 @default.
• W2111479968 countsByYear W21114799682021 @default.
• W2111479968 countsByYear W21114799682022 @default.
• W2111479968 countsByYear W21114799682023 @default.
• W2111479968 crossrefType "journal-article" @default.
• W2111479968 hasAuthorship W2111479968A5039878116 @default.
• W2111479968 hasAuthorship W2111479968A5044887899 @default.
• W2111479968 hasAuthorship W2111479968A5048660181 @default.
• W2111479968 hasAuthorship W2111479968A5071670695 @default.
• W2111479968 hasAuthorship W2111479968A5073338061 @default.
• W2111479968 hasAuthorship W2111479968A5074428655 @default.
• W2111479968 hasAuthorship W2111479968A5074789425 @default.
• W2111479968 hasAuthorship W2111479968A5075347427 @default.
• W2111479968 hasAuthorship W2111479968A5080669646 @default.
• W2111479968 hasAuthorship W2111479968A5089930850 @default.
• W2111479968 hasAuthorship W2111479968A5090256464 @default.
• W2111479968 hasBestOaLocation W21114799681 @default.
• W2111479968 hasConcept C126322002 @default.
• W2111479968 hasConcept C141071460 @default.
• W2111479968 hasConcept C143998085 @default.
• W2111479968 hasConcept C197934379 @default.
• W2111479968 hasConcept C2776256026 @default.
• W2111479968 hasConcept C2776694085 @default.
• W2111479968 hasConcept C2777063308 @default.
• W2111479968 hasConcept C2777240266 @default.
• W2111479968 hasConcept C2778239845 @default.
• W2111479968 hasConcept C2778375690 @default.
• W2111479968 hasConcept C2778850193 @default.
• W2111479968 hasConcept C2781190966 @default.
• W2111479968 hasConcept C2908647359 @default.
• W2111479968 hasConcept C29730261 @default.
• W2111479968 hasConcept C71924100 @default.
• W2111479968 hasConcept C99454951 @default.
• W2111479968 hasConceptScore W2111479968C126322002 @default.
• W2111479968 hasConceptScore W2111479968C141071460 @default.
• W2111479968 hasConceptScore W2111479968C143998085 @default.
• W2111479968 hasConceptScore W2111479968C197934379 @default.
• W2111479968 hasConceptScore W2111479968C2776256026 @default.
• W2111479968 hasConceptScore W2111479968C2776694085 @default.
• W2111479968 hasConceptScore W2111479968C2777063308 @default.
• W2111479968 hasConceptScore W2111479968C2777240266 @default.
• W2111479968 hasConceptScore W2111479968C2778239845 @default.
• W2111479968 hasConceptScore W2111479968C2778375690 @default.
• W2111479968 hasConceptScore W2111479968C2778850193 @default.
• W2111479968 hasConceptScore W2111479968C2781190966 @default.
• W2111479968 hasConceptScore W2111479968C2908647359 @default.
• W2111479968 hasConceptScore W2111479968C29730261 @default.
• W2111479968 hasConceptScore W2111479968C71924100 @default.
• W2111479968 hasConceptScore W2111479968C99454951 @default.
• W2111479968 hasIssue "27" @default.
• W2111479968 hasLocation W21114799681 @default.
• W2111479968 hasLocation W21114799682 @default.

• next